PLRX — Pliant Therapeutics, Inc. Dilution Risk Tracker

Pliant Therapeutics, Inc. (PLRX) has a DilutionScore of 50/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

The most significant dilution vector for PLRX is its shelf registration capacity of $300.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely. Cash runway is a key watch item: PLRX has approximately 16 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for PLRX in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in PLRX's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for PLRX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.